ICAM-1 (intercellular cell-adhesion molecule-1) and VCAM-1 (vascular cell-adhesion molecule-1) are cell-adhesion molecules that have an essential role in monocyte recruitment. In the present study we have investigated (i) whether statins reduce soluble levels of ICAM-1 (sICAM-1) and VCAM-1 (sVCAM-1), and the relationship between resistance of LDL (low-density lipoprotein) to in vitro oxidation and sICAM-1 and sVCAM-1 levels. Whole blood samples were obtained from 55 healthy non-smoking adults (aged 35-65 years) with moderate (LDL-cholesterol, 3.4-4.9 mmol/l) hypercholesterolaemia participating in a randomized double-blinded, 8-week trial comparing pravastatin (40 mg), simvastatin (20 and 80 mg) and placebo. sICAM-1 levels (means + − S.D.) increased slightly from 12.2 + − 4.2 to 13.6 + − 4.2 ng/ml with statin therapy, whereas, among placeboassigned subjects, levels were unchanged (11.8 + − 5.0 and 11.8 + − 3.9 ng/ml). sVCAM-1 increased from 18.9 + − 10.1 to 21.1 + − 7.4 ng/ml among those on active therapy and slightly declined with placebo assignment (19.8 + − 8.8 to 19.4 + − 6.4 ng/ml). Lag times increased with statin therapy from 74.3 + − 39.8 min to 98.3 + − 57.8 min (P = 0.003), and were unchanged in the placebo group (from 103.1 + − 61.1 to 90.8 + − 65.9 min; P = 0.48). There were no significant changes between statin and placebo therapy for sICAM-1, sVCAM-1 or lag times (P = 0.09, 0.16 and 0.067 respectively). Changes in sICAM-1 and sVCAM-1 were not correlated with the change in lag times. In contrast with the known effects of oxidized LDL on gene activation of ICAM-1 and VCAM-1, lag times did not correlate with sICAM-1 and sVCAM-1. Statin therapy improved lag times, but has no effect on sICAM-1 or sVCAM-1 levels.
A B S T R A C T
ICAM-1 (intercellular cell-adhesion molecule-1) and VCAM-1 (vascular cell-adhesion molecule-1) are cell-adhesion molecules that have an essential role in monocyte recruitment. In the present study we have investigated (i) whether statins reduce soluble levels of ICAM-1 (sICAM-1) and VCAM-1 (sVCAM-1), and the relationship between resistance of LDL (low-density lipoprotein) to in vitro oxidation and sICAM-1 and sVCAM-1 levels. Whole blood samples were obtained from 55 healthy non-smoking adults (aged 35-65 years) with moderate (LDL-cholesterol, 3.4-4.9 mmol/l) hypercholesterolaemia participating in a randomized double-blinded, 8-week trial comparing pravastatin (40 mg), simvastatin (20 and 80 mg) and placebo. sICAM-1 levels (means + − S.D.) increased slightly from 12.2 + − 4.2 to 13.6 + − 4.2 ng/ml with statin therapy, whereas, among placeboassigned subjects, levels were unchanged (11.8 + − 5.0 and 11.8 + − 3.9 ng/ml). sVCAM-1 increased from 18.9 + − 10.1 to 21.1 + − 7.4 ng/ml among those on active therapy and slightly declined with placebo assignment (19.8 + − 8.8 to 19.4 + − 6.4 ng/ml). Lag times increased with statin therapy from 74.3 + − 39.8 min to 98.3 + − 57.8 min (P = 0.003), and were unchanged in the placebo group (from 103.1 + − 61.1 to 90.8 + − 65.9 min; P = 0.48). There were no significant changes between statin and placebo therapy for sICAM-1, sVCAM-1 or lag times (P = 0.09, 0.16 and 0.067 respectively). Changes in sICAM-1 and sVCAM-1 were not correlated with the change in lag times. In contrast with the known effects of oxidized LDL on gene activation of ICAM-1 and VCAM-1, lag times did not correlate with sICAM-1 and sVCAM-1. Statin therapy improved lag times, but has no effect on sICAM-1 or sVCAM-1 levels.
ICAM-1 (intercellular cell-adhesion molecule-1) and VCAM-1 (vascular cell-adhesion molecule-1) are cell-adhesion molecules that have an essential role in leucocyte adhesion, recruitment and transendothelial migration. Oxidized LDL (low-density lipoprotein) and proinflammatory cytokines, such as TNF-α (tumour necrosis factor-α), induce expression of cell-adhesion molecules by endothelial cells and their ligands on leucocytes. Rezaie-Majd et al. [1] have reported that incubation of HUVECs (human umbilical vein endothelial cells) with TNF-α increased surface expression of ICAM-1. Statins (atorvastatin, cerivastastin and simvastatin)
Table 1 Characteristics of lipids, lipoproteins, soluble cell-adhesion molecules and lag times by treatment group
Values are means + − S.D., with the exception of lag times which are medians (inter-quartile range). There are no differences in any baseline lipids, lipoproteins, soluble cell-adhesion molecules or lag times across assigned groups.
* Within group comparisons were evaluated using Student's t tests for normal data, and Wilcoxon signed-rank tests were used to evaluate non-normal data. There were no group differences for ICAM-1 (P = 0.09), VCAM-1 (P = 0.16) or lag time (P = 0.067). inhibited HUVEC expression of CD54, which is the cognate ligand for ICAM-1. Oxidized LDL induces a dose-dependent increase in ICAM-1 and VCAM-1 expression [2] . This induction is reduced by the radicalscavenging antioxidant probucol. In contrast with these favourable effects of statins on the expression of ICAM-1 and VCAM-1, Jilma et al. [3] report that 12-week therapy with atorvastatin, pravastatin or simvastatin did not alter circulating levels of ICAM-1 (sICAM-1) and VCAM-1 (sVCAM-1) in 75 hypercholesterolaemic subjects. In the present study, we have investigated (i) whether simvastatin or pravastatin therapy reduces sICAM-1 and sVCAM-1, and (ii) the relationship between resistance of LDL to in vitro oxidation and sICAM-1 and sVCAM-1 levels.
Whole blood samples were obtained from 55 healthy non-smoking adults (aged 35-65 years) with moderate (LDL-cholesterol, 3.4-4.9 mmol/l) hypercholesterolaemia participating in a randomized double-blinded, 8-week trial comparing 40 mg of pravastatin, 20 or 80 mg of simvastatin and placebo. Subjects were 51 + − 8 years of age (mean + − S.D.), 70 % male, 81 % white, 11 % black, and had a BMI (body mass index) of 27.6 + − 4.6 kg/m 2 . All subjects were free of inflammatory disorders and prohibited from using antioxidant vitamins, anti-inflammatory agents or lipid-altering agents. Blood samples were acquired after a 12 h fast for analysis of lipoproteins and resistance to copper-mediated LDL oxidation (lag time in min). Pretreatment and post-treatment levels of plasma lipids, lipoproteins, sICAM-1, sVCAM-1 as well as lag times are shown in Table 1 . sICAM-1 and sVCAM-1 were analysed using ELISA. Intra-assay coefficients of variation in our laboratory are 5.2 % for sICAM-1 and 6.5 % and 5.5 % for separate sVCAM assays.
Although there were significant differences in the magnitude of lipid-lowering across treatment with the statin agents, there were no differences in the individual statin agents on sICAM-1 and sVCAM-1 levels, so the active treatments were combined. There were no significant changes between statin and placebo therapy for sICAM-1 or sVCAM-1 levels (P = 0.09 and 0.16 respectively). Mean sICAM-1 levels increased slightly from 12.2 to 13.6 ng/ml with statin therapy, whereas, among placebo-assigned subjects, levels were essentially unchanged (11.8 ng/ml). Mean sVCAM-1 levels increased from 18.9 to 21.1 ng/ml among those on active therapy and slightly declined with placebo assignment (from 19.8 to 19.4 ng/ml). Lag times significantly increased with statin therapy (P = 0.003) and were unchanged in the placebo group (group difference, P = 0.067). In contrast with the known effects of oxidized LDL on gene activation of ICAM-1 and VCAM-1, lag times did not correlate with sICAM-1 (r = − 0.14, P = 0.42) and sVCAM-1 (r = − 0.09, P = 0.60) in statintreated subjects.
Our results are consistent with the negative findings of Jilma et al. [3] on circulating levels of cell-adhesion molecules. These discrepant findings on TNF-α-stimulated CD54 expression and circulating levels of celladhesion molecules may result from the differential effect of statins on leucocyte compared with endothelial adhesion molecules.
